Rodman & Renshaw Initiates Coverage on Orexigen Therapeutics (OREX) with a Market Outperform
More News related to OREX
- Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
- Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009
- Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Rodman & Renshaw initiates coverage on Orexigen Therapeutics (Nasdaq: OREX) with a Market
Outperform rating. Price target $14
Rodman analyst says, "We view the company's obesity drug, Contrave, as promising relative to obesity drugs in development and on the market."
To see more analyst ratings on OREX Click Here.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity.
Related Categories
New CoverageStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
